Paul Edison
Works at
Lead investigator
Sources: openalex.org
Grants and prizes
Alzheimer's Drug Discovery Foundation
Clinical, Evaluating the effects of GLP-1 analog, oral semaglutide, as a treatment for sporadic behavioral variant frontotemporal dementia (bvFTD), ADDF-21528271, 2022–2025, 1 Feb 2022
PTC, Evaluating oral semaglutide as a treatment for Alzheimer's disease, PTC REG-20-653530, 2020, 1 Jan 2020
Sources: openalex.org